Clinical Trial Update: Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating Gallium-68 Edotreotide PET/CT imaging for patients with advanced gastroenteropancreatic neuroendocrine tumors and is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Gallium-68 Edotreotide (edotreotide)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Advanced Gastroenteropancreatic Neuroendocrine Tumor | Phase 3 | Status: RECRUITING